Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 12/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | HGFAC | Q04756 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.41 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.41 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11961792 | 0.91 | ELANE (0.56) | ELANEHGFACKMT2AESR1MEN1 | |
| SCHEMBL18773640 | 0.89 | ELANE (0.51) | ELANECA2KMT2A | |
| SCHEMBL30744224 | 0.85 | ELANE (0.55) | ELANECA2HGFACKMT2AESR1 | |
| SCHEMBL27322408 | 0.85 | ELANE (0.55) | ELANECA2HGFACKMT2AESR1 | |
| SCHEMBL30744223 | 0.85 | ELANE (0.55) | ELANECA2HGFACKMT2AESR1 | |
| SCHEMBL18388112 | 0.84 | ELANE (0.46) | ELANECA2KMT2AMEN1 | |
| SCHEMBL22566576 | 0.82 | ELANE (0.48) | ELANEKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL20507042 | 0.82 | ELANE (0.50) | ELANECA2HGFACKMT2AMEN1 | |
| SCHEMBL20349430 | 0.81 | ELANE (0.50) | ELANEMAPTTDP1 | |
| SCHEMBL26312594 | 0.81 | HGFAC (0.54) | ELANECA2HGFACKMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210214299-A1 | POLYMERIZABLE COMPOUND, AND LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE USING THE SAME | DIC CORPORATION (JP) | 2021-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210214299-A1 | POLYMERIZABLE COMPOUND, AND LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE USING THE SAME | SKP1, PKN1, KTN1 | ELANE 4055/4885CA2 3992/4885HGFAC 4234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.